欧罗巴：关于血管紧张素转换酶抑制剂有什么新的发现吗？
EUROPA: has anything new been learned with angiotensin-converting enzyme inhibitors?
作者信息
Sica Domenic A
机构信息
Department of Medicine, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298-0160, USA.
出版信息
J Clin Hypertens (Greenwich). 2004 Feb;6(2):91-5. doi: 10.1111/j.1524-6175.2004.02846.x.
The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease (EUROPA) involved 12,218 patients with stable coronary artery disease. Patients in this trial were randomized to the angiotensin-converting enzyme inhibitor perindopril (8 mg/d) or placebo in addition to optimized conventional therapy and followed for an average of 4 years. Perindopril reduced the primary end points of cardiovascular disease, myocardial infarction, and cardiac arrest by 20% (p=0.0003). Moreover, the angiotensin-converting enzyme inhibitor reduced the rate of fatal and nonfatal myocardial infarction by 24% (p=0.001). The results from EUROPA complement those observed in the Heart Outcomes and Prevention Evaluation (HOPE) study and provide further support for the concept of angiotensin-converting enzyme inhibitors conferring cardiovascular protection as a class effect.
欧洲培哚普利降低稳定型冠状动脉疾病心脏事件试验（EUROPA）纳入了12218例稳定型冠状动脉疾病患者。该试验中的患者在优化的传统治疗基础上，被随机分为接受血管紧张素转换酶抑制剂培哚普利（8毫克/天）或安慰剂治疗，并平均随访4年。培哚普利使心血管疾病、心肌梗死和心脏骤停的主要终点降低了20%（p = 0.0003）。此外，该血管紧张素转换酶抑制剂使致命和非致命性心肌梗死的发生率降低了24%（p = 0.001）。EUROPA的结果补充了心脏结局预防评估（HOPE）研究中观察到的结果，并为血管紧张素转换酶抑制剂作为一类药物具有心血管保护作用这一概念提供了进一步支持。
Zotero 插件